Abstract: The present invention relates to neuronal death inhibitors containing, as its active ingredient, a compound represented by the following formula (1): 1

Abstract: A prophylactic and/or therapeutic method for treating a disease caused by mitochondrial functional abnormality, or a disease with mitochondrial functional abnormality, including: administering a prophylactically and/or therapeutically effective amount to a patient in need of such treatment of a medicament including as an active ingredient a substance having a stabilizing effect on mitochondrial membrane by suppressing or eliminating depolarization of mitochondrial membranes which is caused by elevation of intracellular calcium ion concentration, wherein the stabilizing effect on mitochondrial membrane is an action of suppressing or eliminating depolarization of mitochondrial membranes, wherein the depolarization of mitochondrial membranes is caused by elevation of intracellular calcium ion concentration. The disease may be ischemic diseases, toxic diseases, or degenerative diseases. The medicament may be 2-oxo-1-pyrrolidinylacetic acid 2,6-dimethylanilide which acts as a benzodiazepine receptor antagonist.

Abstract: A therapeutic or preventive agent for intractable epilepsy comprising as an active ingredient a compound represented by R2—CH2CONH—R1 (I), wherein R1 is a phenyl group or a pyridyl group, which may have a substituent and R2 is a 2-oxo-1-pyrrolidinyl group which may have a substituent.

Abstract: An medicament for preventive and/or therapeutic treatment of a disease caused by mitochondrial functional abnormality, or a disease with mitochondrial functional abnormality, e.g., ischemic diseases, toxic diseases, degenerative diseases, which comprises as an active ingredient a substance having a stabilizing effect on mitochondrial membrane by stabilizing mitochondrial membrane potential, e.g., 2-oxo-1-pyrrolidinylacetic acid 2,6-dimethylanilide which acts as a benzodiazepine receptor antagonist.

Abstract: A medicament which comprises as an active ingredient a compound represented by the following formula: R.sup.2 -CH.sub.2 CONH-R.sup.1 wherein R.sup.1 represents a pyridyl group, a substituted pyridyl group, phenyl group, or a substituted phenyl group; and R.sup.2 represents 2-oxo-1-pyrrolidinyl group which may optionally be substituted, and inhibits the development of dependency induced by a narcotic analgesic and/or inhibit the development of tolerance to analgesic action induced by a narcotic analgesic agent.